Search

Displaying results 1431 - 1440 of 4236 in total
  1. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48596] Existing treatments for chronic cough have been associated with considerable side effects, in particular opioids such as [codeine] or [dextromethorphan].

  2. Drug

    Sodium bisulfite

    go.drugbank.com/drugs/DB14015
    ApprovedWithdrawn

    Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

  3. Drug

    Fenoterol

    go.drugbank.com/drugs/DB01288
    ApprovedWithdrawn

    Fenoterol is an adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.

  4. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].

  5. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  6. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI).

  7. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore … [L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular

  8. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter. … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

  9. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  10. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although … GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series